Oslo, Norway, 25 March 2022

Reference is made to the stock exchange announcement made by Nordic Nanovector
ASA (OSE: NANOV) (the "Company") on 23 March 2022 regarding the settlement of
42,675 PSUs.

The share capital increase pertaining to the settled PSUs has now been
registered in the Norwegian Register of Business Enterprises (the "NRBE") on 25
March 2022. The Company's share capital has been increased with NOK 8,535
through the issuance of 42,675 new shares.

Following registration of the share capital increase related to the new shares
in the NRBE, the Company has an issued share capital of NOK 23,207,059.60,
divided into 116,035,298 shares, each with a par value of NOK 0.20. Each share
represents one vote in the Company's general meeting.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)

Tel: +44 207 638 9571

Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of CD37-targeted therapies
for haematological cancers and immune diseases. Nordic Nanovector's lead
clinical-stage candidate is Betalutin[®], a novel CD37-targeting
radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma
(NHL). NHL is an indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 27 billion by 2029. Nordic
Nanovector retains global marketing rights to Betalutin[®] and intends to
actively participate in the commercialisation of Betalutin[®] in the US and
other major markets.

Further information can be found at
www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url=ht
t
p%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrava.c
o
m%7Cbd8fdb7f05284d3963a108d9d20ae447%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C0%
7
C637771766496096573%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIi
L
CJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=xp8WBxqCMdEa4qM%2FjJAyw9bnfalGpQqswXz
S
zRJqqWo%3D&reserved=0).

This information is subject to the disclosure requirements pursuant to Oslo Rule
Book II section 4.3.5.5 (4).